Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.68 |
| ▸ | PIK3R1 | P27986 | 14/20 | 0.68 |
| ▸ | PIK3C3 | Q8NEB9 | 6/20 | 0.66 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.60 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26198636 | 0.90 | PIK3CA (0.68) | PIK3CAPIK3R1PIK3C3PIK3CBPIK3CG | |
| SCHEMBL26198670 | 0.88 | PIK3CA (0.77) | PIK3CAPIK3R1PIK3C3PIK3CBPIK3CG | |
| SCHEMBL16751436 | 0.87 | PIK3CA (0.79) | PIK3CAPIK3R1PIK3C3PIK3CBPIK3CG | |
| SCHEMBL9954680 | 0.86 | PIK3CA (0.68) | PIK3CAPIK3R1PIK3C3PIK3CBPIK3CG | |
| SCHEMBL9954673 | 0.86 | PIK3CA (0.68) | PIK3CAPIK3R1PIK3C3PIK3CBPIK3CG | |
| SCHEMBL9955527 | 0.84 | PIK3CA (0.73) | PIK3CAPIK3R1PIK3C3PIK3CBPIK3CG | |
| SCHEMBL9953752 | 0.83 | PIK3CA (0.68) | PIK3CAPIK3R1PIK3C3PIK3CBPIK3CG | |
| SCHEMBL9960770 | 0.83 | PIK3CA (0.68) | PIK3CAPIK3R1PIK3C3PIK3CBPIK3CG | |
| SCHEMBL9955435 | 0.83 | PIK3CA (0.68) | PIK3CAPIK3R1PIK3C3PIK3CBPIK3CG | |
| SCHEMBL9955440 | 0.83 | PIK3CA (0.68) | PIK3CAPIK3R1PIK3C3PIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739100-B2 | 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | SANOFI (FR) | 2023-08-29 | — | — | US | disclosed |
| US-11739100-B2 | 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | SANOFI (FR) | 2023-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739100-B2 | 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | CBR3, MTX1, CBR1 | PIK3CA 3644/4885PIK3R1 2358/4885PIK3C3 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.